Today's Rundown Featured Story | | | Friday, April 5, 2019 Merrimack is dumping another cancer therapy after a recent trial flagged adverse event worries, leading the biotech to swing the ax across its already severely depleted workforce as it gives up on its third and final clinical shot on goal. |
|
|
Top Stories Thursday, April 4, 2019 After attesting to its use in ovarian, breast and pancreatic cancers, the trio of AstraZeneca, Merck & Co. and Myriad Genetics is now bringing the latter’s companion diagnostic to bear on metastatic castration-resistant prostate cancer. The BRACAnalysis CDx test will be used to hunt for BRCA mutations in men eligible for the Big Pharmas’ PARP-inhibiting Lynparza therapy. Friday, April 5, 2019 Montreal-based NeuroServo is working on an EEG device that could become an objective test for delirium, replacing standardized but subjective questionnaires that are the current standard for diagnosing the condition. Monday, April 1, 2019 Deloitte discusses how biotech companies are exploring alternative strategies to fund growth including IPOs, collaborative arrangements, and share-based payment arrangements. Friday, April 5, 2019 In this week's EuroBiotech Report, Cambridge Innovation Capital committed nearly $200 million to biotechs, agnostic mAb maker AgomAb got off a healthy series A, Novartis penned a potential $1.6 billion biobucks pact with IFM and Galapagos reported positive data for JAK inhibitor filgotinib. Friday, April 5, 2019 Daiichi Sankyo nabbed a $6.9 billion antibody drug conjugate deal with AstraZeneca as it appointed a new CEO; Keytruda became the first PD-1/L1 to land a Chinese nod in untreated non-small cell lung cancer; Chi-Med rolled out positive data for MET inhibitor savolitinib; and more. Friday, April 5, 2019 Soon-Shiong sued over "catch-and-kill" of potential Abraxane rival drug; Gottlieb reflects on his tenure before joining the club of ex-FDA chiefs; and British biotech Artios nabs Eli Lilly, AstraZeneca R&D veteran. Those moves plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Data MATRIX | 3:00 AM EDT / 9:00 AM EDT / 2:00 PM EDT How to cut a study budget by 4 times? How to process CRFs 3 times faster? What made a CRO switch from a US vendor to Data MATRIX? In 45 minutes, we will dissolve myths about entering the market. Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
